Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 18;8(2):92-106.
doi: 10.4254/wjh.v8.i2.92.

Chronic hepatitis C: This and the new era of treatment

Gaetano Bertino  1 , Annalisa Ardiri  1 , Maria Proiti  1 , Giuseppe Rigano  1 , Evelise Frazzetto  1 , Shirin Demma  1 , Maria Irene Ruggeri  1 , Laura Scuderi  1 , Giulia Malaguarnera  1 , Nicoletta Bertino  1 , Venerando Rapisarda  1 , Isidoro Di Carlo  1 , Adriana Toro  1 , Federico Salomone  1 , Mariano Malaguarnera  1 , Emanuele Bertino  1 , Michele Malaguarnera  1
Affiliations
Review

Chronic hepatitis C: This and the new era of treatment

Gaetano Bertino et al. World J Hepatol. .

Abstract

Over the last years it has started a real revolution in the treatment of chronic hepatitis C. This occurred for the availability of direct-acting antiviral agents that allow to reach sustained virologic response in approximately 90% of cases. In the near future further progress will be achieved with the use of pan-genotypic drugs with high efficacy but without side effects.

Keywords: Boceprevir; Daclatasvir; Dasabuvir; Direct-acting antiviral agents; Faldaprevir; Hepatitis C; Ledipasvir; Nucleoside inhibitors; Ombitasvir; Ritonavir; Simeprevir; Sofosbuvir; Telaprevir.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hepatitis C virus replicative cycle and main targets for direct acting antiviral agents. Modified from Manns and Cornberg. Lancet Infectious Diseases 2013. PIs: Protease inhibitors; NPIs: Nucleoside polymerase inhibitors; NNPIs: Non-nucleoside polymerase inhibitors.
Figure 2
Figure 2
Direct acting antiviral agents. Modified from Alexopoulou et al[121]. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Annals of Gastroenterology 2015; 28: 55-65. NPIs: Nucleoside polymerase inhibitors; NNPIs: Non-nucleoside polymerase inhibitors; DAA: Direct acting antiviral.
Figure 3
Figure 3
ION-2 sub-analysis of cirrhosis vs without cirrhosis. Error bars represent 95%CIs. LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir; SVR12: Sustained virologic response at 12 wk post-treatment.
See this image and copyright information in PMC

References

    1. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–521, 521.e1-6. - PubMed
    1. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014;21 Suppl 1:34–59. - PubMed
    1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538. - PubMed
    1. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–477. - PubMed
    1. Malaguarnera M, Scuderi L, Ardiri Al, Malaguarnera G, Bertino N, Ruggeri IM, Carmela Greco G, Ozyalcn E, Bertino E, Bertino G. Type II Mixed Cryoglobulinemia in patients with Hepatitis C Virus: treatment with Pegylated-interferon and ribavirin. Acta Medica Mediterr. 2015;31:431.

LinkOut - more resources